What Is TB-500? Thymosin Beta-4 Fragment Guide
What TB-500 is, how the synthetic fragment differs from full-length thymosin beta-4, and where the published evidence is still thin.
For research use only. Not for human consumption. TB-500 is not approved by the FDA for human use and is sold as a research chemical. Not medical advice.
Summaries of published research, cited to the source
What TB-500 (a thymosin beta-4 fragment) is, what cell, animal and early human studies actually show, its safety unknowns, and its FDA and WADA status.
TB-500 is not approved by the FDA for human use and is sold only as a research chemical. We separate preclinical findings from human evidence and never give dosing advice for people.
TB-500 at a glance
TB4 is the full protein; TB-500 is the fragment built from it. Thymosin Beta-4 (TB4, Tβ4) is a naturally occurring 43-amino acid protein present in nearly every cell in the body. TB-500 is a synthetic 7-amino acid peptide — amino acids 17-23 of that protein — manufactured because it carries the actin-binding activity researchers care about, without the cost of producing the full-length molecule.
They are related, not identical. TB-500 shares TB4's core actin-regulation mechanism, but not every downstream effect attributed to full-length TB4 has been demonstrated for the fragment specifically — and because "TB-500" is a commercial name rather than a standardized one, some suppliers use it loosely for either molecule. If you're comparing the two for research purposes, the sequence on the certificate of analysis matters more than the name on the label.
Read the Full TB-500 vs TB4 Comparison →Information grounded in published studies on thymosin beta-4 and its synthetic fragments, referencing real scientific literature.
How published studies reported dose, route, and timing, and why those figures are research context rather than instructions for people.
Honest safety profiles, side effect research, and head-to-head comparisons with other peptides like BPC-157.
What TB-500 is, how the synthetic fragment differs from full-length thymosin beta-4, and where the published evidence is still thin.
How TB-500 research describes actin binding, cell migration, angiogenesis, and inflammation. Most of the evidence is from cells and animals.
Which TB-500 effects show up in preclinical studies, and which popular claims still lack human evidence. Research summary only.
What published research and case discussion actually show about TB-500 side effects, theoretical risks, and unstudied drug combinations.
What tendon, ligament, and joint research on thymosin beta-4 covers. No specific injury listed here has a controlled TB-500 trial in people.
How to judge TB-500 research-chemical vendors, certificates of analysis, purity testing, and salt form. For laboratory research only.
No. Thymosin Beta-4 (TB4 or Tβ4) is the full 43-amino acid protein made naturally in nearly every human and animal cell. TB-500 is a synthetic peptide built from just the active fragment of that protein — amino acids 17-23, the region responsible for actin binding. TB-500 is derived from TB4 and shares its core mechanism, but the two are not interchangeable in size, research history, or (in some cases) what a vendor actually ships in the vial. See our full breakdown for the exact differences.
TB-500 is a synthetic peptide fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid protein found in nearly all human and animal cells. It plays a key role in tissue repair, cell migration, and inflammation regulation. TB-500 specifically consists of the active region of Tβ4 (amino acids 17-23) responsible for actin binding and cell motility.
TB-500 works primarily by upregulating actin, a cell-building protein essential for tissue repair. It promotes angiogenesis (new blood vessel formation), reduces inflammation, and enhances cell migration to injury sites. Research suggests it activates satellite cells in muscle tissue and promotes keratinocyte migration for wound healing.
While both are healing peptides, they work through different mechanisms. TB-500 primarily promotes systemic healing through actin regulation and cell migration, while BPC-157 works locally through growth factor modulation and gut-healing properties. Combinations are often discussed online, but there are no controlled human studies showing the pair is safe or more effective together.
TB-500 is not approved by the FDA for human use. In the U.S. it is marketed only as a research chemical labeled not for human consumption, and FDA has flagged thymosin beta-4 fragments as raising safety concerns for pharmacy compounding. It is prohibited by WADA and most sports bodies. Rules vary by country, so check local law.
Published research in journals like the Annals of the New York Academy of Sciences and FASEB Journal has shown thymosin beta-4 promotes wound healing, reduces inflammation, and supports cardiac tissue repair in animal models. The peptide has demonstrated promise for tendon, ligament, muscle, and skin repair in preclinical studies.
The buy guide covers vendor checks, COAs, and red flags. It links to a real research-peptide source. TB-500 is not FDA-approved for human use and is sold for laboratory research only.
Read Where to Buy TB-500 →New dosage guides, study breakdowns, and protocol updates — delivered to your inbox. No spam, unsubscribe anytime.